Copy number imbalances between screen- and symptom-detected breast cancers and impact on disease-free survival

Cancer Prevention Research

Volumn 4, Issue 10, 2011, Pages 1609-1616

  Brewster, A M ^a   Thompson, P ^b   Sahin, A A ^a   Do, K ^a   Edgerton, M ^a   Murray, J L ^a   Tsavachidis, S ^a   Zhou, R ^a   Liu, Y ^a   Zhang, L ^a   Mills, G ^a   Bondy, M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; KI 67 ANTIGEN; TAMOXIFEN; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CHROMOSOME 11P; CHROMOSOME 20Q; CHROMOSOME 2P; CHROMOSOME 3Q; CHROMOSOME 8Q; COPY NUMBER IMBALANCE; COPY NUMBER VARIATION; DISEASE FREE SURVIVAL; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COHORT STUDIES; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASS SCREENING; MIDDLE AGED; NEOPLASM GRADING; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 80053903077     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0361     Document Type: Article

References (56)

1. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med 2009;151:727-37, W237-42.
2. Immonen-Räihä P, Kauhava L, Parvinen I, Holli K, Kronqvist P, Pylkkänen L, et al. Mammographic screening reduces risk of breast carcinoma recurrence. Cancer 2005;103:474-82.
3. Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 2005;97:1195-203. (Pubitemid 41258225)
4. Dong W, Berry DA, Bevers TB, Kau SW, Hsu L, Theriault RL, et al. Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev 2008;17:1096-103.
5. Joensuu H, Lehtimäki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, et al. Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 2004;292:1064-73. (Pubitemid 39129196)
6. Chu KC, Smart CR, Tarone RE. Analysis of breast cancer mortality and stage distribution by age for the Health Insurance Plan clinical trial. J Natl Cancer Inst 1988;80:1125-32.
7. Sihto H, Lundin J, Lehtimäki T, Sarlomo-Rikala M, Bützow R, Holli K, et al. Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res 2008;14:4103-10.
8. Friedrich K, von Heydebreck A, Haroske G, Scheithauer J, Meyer W, Kunze KD, et al. Comparative genomic hybridization-based oncogenetic tree model for genetic classification of breast cancer. Anal Quant Cytol Histol 2009;31:101-8.
9. Rennstam K, Ahlstedt-Soini M, Baldetorp B, Bendahl PO, Borg A, Karhu R, et al. Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. Cancer Res 2003;63:8861-8. (Pubitemid 38064066)
10. van Beers EH, Nederlof PM. Array-CGH and breast cancer. Breast Cancer Res 2006;8:210.
11. Letessier A, Sircoulomb F, Ginestier C, Cervera N, Monville F, Gelsi-Boyer V, et al. Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer 2006;6:245.
12. Brewster AM, Do KA, Thompson PA, Hahn KM, Sahin AA, Cao Y, et al. Relationship between epidemiologic risk factors and breast cancer recurrence. J Clin Oncol 2007;25:4438-44. (Pubitemid 350013850)
13. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101:736-50.
14. Wang Y, Carlton VE, Karlin-Neumann G, Sapolsky R, Zhang L, Moorhead M, et al. High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays. BMC Med Genomics 2009;2:8.
15. Hardenbol P, Yu F, Belmont J, Mackenzie J, Bruckner C, Brundage T, et al. Highly multiplexed molecular inversion probe genotyping: over 10,000 targeted SNPs genotyped in a single tube assay. Genome Res 2005;15:269-75. (Pubitemid 40309391)
16. Hardenbol P, Banér J, Jain M, Nilsson M, Namsaraev EA, Karlin-Neumann GA, et al. Multiplexed genotyping with sequence-tagged molecular inversion probes. Nat Biotechnol 2003;21:673-8. (Pubitemid 36638095)
17. Wang Y, Moorhead M, Karlin-Neumann G, Falkowski M, Chen C, Siddiqui F, et al. Allele quantification using molecular inversion probes (MIP). Nucleic Acids Res 2005;33:e183.
18. Ji H, Kumm J, Zhang M, Farnam K, Salari K, Faham M, et al. Molecular inversion probe analysis of gene copy alterations reveals distinct categories of colorectal carcinoma. Cancer Res 2006;66:7910-9. (Pubitemid 44299153)
19. Wang Y, Moorhead M, Karlin-Neumann G, Wang NJ, Ireland J, Lin S, et al. Analysis of molecular inversion probe performance for allele copy number determination. Genome Biol 2007;8:R246.
20. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004;5:557-72. (Pubitemid 41180205)
21. Westfall PH, Young SS. Resampling-based multiple testing: examples and methods for p-value adjustment. New York: Wiley; 1993.
22. Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med 1992;11:167-78.
23. Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA, et al. Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screendetected cancers. J Natl Cancer Inst 1999;91:2020-8.
24. Crosier M, Scott D, Wilson RG, Griffiths CD, May FE, Westley BR. Differences in Ki67 and c-erbB2 expression between screendetected and true interval breast cancers. Clin Cancer Res 1999;5:2682-8. (Pubitemid 29493939)
25. Gilliland FD, Joste N, Stauber PM, Hunt WC, Rosenberg R, Redlich G, et al. Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 2000;92:743-9. (Pubitemid 30365535)
26. Groenendijk RP, Bult P, Tewarie L, Peer PG, van der Sluis RF, Ruers TJ, et al. Screen-detected breast cancers have a lower mitotic activity index. Br J Cancer 2000;82:381-4. (Pubitemid 30045385)
27. Hakama M, Holli K, Isola J, Kallioniemi OP, Kärkkäinen A, Visakorpi T, et al. Aggressiveness of screen-detected breast cancers. Lancet 1995;345:221-4.
28. Klemi PJ, Toikkanen S, Rasanen O, Parvinen I, Joensuu H. Mammography screening interval and the frequency of interval cancers in a population-based screening. Br J Cancer 1997;75:762-6. (Pubitemid 27091095)
29. Dawson SJ, Duffy SW, Blows FM, Driver KE, Provenzano E, LeQuesne J, et al. Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. Br J Cancer 2009;101:1338-44.
30. Gunther K, Merkelbach-Bruse S, Amo-Takyi BK, Handt S, Schroder W, Tietze L. Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization. J Pathol 2001;193:40-7. (Pubitemid 32051111)
31. Nishizaki T, Chew K, Chu L, Isola J, Kallioniemi A, Weidner N, et al. Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int J Cancer 1997;74:513-7. (Pubitemid 27486508)
32. Courjal F, Theillet C. Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification. Cancer Res 1997;57:4368-77. (Pubitemid 27413448)
33. Richard F, Pacyna-Gengelbach M, Schlüns K, Fleige B, Winzer KJ, Szymas J, et al. Patterns of chromosomal imbalances in invasive breast cancer. Int J Cancer 2000;89:305-10. (Pubitemid 30430749)
34. Bergamaschi A, Kim YH, Wang P, Sørlie T, Hernandez-Boussard T, Lonning PE, et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 2006;45:1033-40. (Pubitemid 44435537)
35. van Beers EH, van WelsemT, Wessels LF, Li Y, Oldenburg RA, Devilee P, et al. Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res 2005;65:822-7. (Pubitemid 40216440)
36. Waddell N, Arnold J, Cocciardi S, da Silva L, Marsh A, Riley J, et al. Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Res Treat 2009;123:661-77.
37. Wessels LF, van Welsem T, Hart AA, van't Veer LJ, Reinders MJ, Nederlof PM. Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res 2002;62:7110-7. (Pubitemid 35424107)
38. Melchor L, Honrado E, García MJ, Alvarez S, Palacios J, Osorio A, et al. Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes. Oncogene 2008;27:3165-75. (Pubitemid 351693170)
39. Stefansson OA, Jonasson JG, Johannsson OT, Olafsdottir K, Steinarsdottir M, Valgeirsdottir S, et al. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res 2009;11:R47.
40. Kang JH, Lee YY, Yu BY, Yang BS, Cho KH, Yoon DK, et al. Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. Arch Pharm Res 2005;28:1263-9.
41. Dieudonne MN, Bussiere M, Dos Santos E, Leneveu MC, Giudicelli Y, Pecquery R. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun 2006;345:271-9.
42. Körner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, Kaprara A, et al. Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 2007;92:1041-8. (Pubitemid 46465681)
43. Wang Y, Lam JB, Lam KS, Liu J, Lam MC, Hoo RL, et al. Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 2006;66:11462-70. (Pubitemid 46009979)
44. Arditi JD, Venihaki M, Karalis KP, Chrousos GP. Antiproliferative effect of adiponectin on MCF7 breast cancer cells: a potential hormonal link between obesity and cancer. Horm Metab Res 2007;39:9-13. (Pubitemid 46535150)
45. Uchino M, Kojima H, Wada K, Imada M, Onoda F, Satofuka H, et al. Nuclear beta-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells. BMC Cancer 2010;10:414.
46. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15. (Pubitemid 351636299)
47. Celebiler Cavusoglu A, Kilic Y, Saydam S, Canda T, Başkan Z, Sevinc AI, et al. Predicting invasive phenotype with CDH1, CDH13, CD44, and TIMP3 gene expression in primary breast cancer. Cancer Sci 2009;100:2341-5.
48. Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, et al. The CD44+/CD24- phenotype is enriched in basallike breast tumors. Breast Cancer Res 2008;10:R53.
49. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010;102:605-13.
50. Paci E, Warwick J, Falini P, Duffy SW. Overdiagnosis in screening: is the increase in breast cancer incidence rates a cause for concern? J Med Screen 2004;11:23-7. (Pubitemid 38365691)
51. Zackrisson S, Andersson I, Janzon L, Manjer J, Garne JP. Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study. BMJ 2006;332:689-92.
52. Zahl PH, Strand BH, Maehlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ 2004;328:921-4. (Pubitemid 38496981)
53. Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med 2009;151:738-47.
54. van der Vegt B, Wesseling J, Pijnappel RM, Dorrius MD, den Heeten GJ, de Roos MA, et al. Aggressiveness of 'true' interval invasive ductal carcinomas of the breast in postmenopausal women. Mod Pathol 2010;23:629-36.
55. Holloway CM, Easson A, Escallon J, Leong WL, Quan ML, Reedjik M, et al. Technology as a force for improved diagnosis and treatment of breast disease. Can J Surg 2010;53:268-77.
56. Ellsworth RE, Hooke JA, Love B. Molecular changes in primary breast tumors and Nottingham histological score. Pathol Oncol Res 2009;15:541-47.